Vertex Pharmaceuticals (NASDAQ: VRTX) is known for its blockbuster cystic fibrosis treatments. The company generates billions of dollars in revenue and profit from them annually, and it looks as if that's set to continue for quite some time. The closest potential competitor for Vertex's top-selling product is actually a candidate in its own pipeline.
That may be a good reason to buy shares of this biotech company, but I've got an even better one. Vertex today has six programs that are in mid-to-late-stage clinical trials, and during its recent first-quarter earnings call, management said they represent "multibillion-dollar opportunities."
Image source: Getty Images.
For further details see:
Here's the No. 1 Reason to Buy Vertex Pharmaceuticals Now